Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Acetabular and Sacral Insufficiency Fractures in a Patient With a Long-Term History of Alendronate Consumption; a Case Report Publisher Pubmed



Gharanizadeh K1, 2 ; Ravanbod H1, 2, 3 ; Aminian A2 ; Hatami S4 ; Chaleshtori AS4 ; Kazerani S4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Shafa Orthopedic Hospital, Iran University of Medical Science, Tehran, Iran
  2. 2. Bone and Joint Reconstruction Research Center, Department of Orthopedics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Orthopedic Surgery, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran

Source: BMC Musculoskeletal Disorders Published:2023


Abstract

Background: Long-term Bisphosphonate consumption has been reported to be associated with the incidence of atypical or insufficiency fracture, particularly in the proximal femur. We observed a case of acetabular and sacral insufficiency fractures in a patient with a long-term history of Alendronate consumption. Case presentation: A 62-year-old woman was admitted with a complaint of pain in right lower limb following low-energy trauma. The patient had a history of Alendronate consumption for more than 10 years. The bone scan revealed increased radiotracer uptake in the right side of the pelvic, proximal right femur, and sacroiliac joint. The radiographs showed type 1 sacrum fracture, acetabulum fracture with femur head protrusion into the pelvis, quadrilateral surface fracture, fracture of the right anterior column, and right superior and inferior pubic fracture. The patient was treated with total hip arthroplasty. Conclusion: This case highlights the concerns regarding long-term bisphosphonate therapy and its potential complications. © 2023, The Author(s).